AI assistant
VOLITIONRX LTD — Director's Dealing 2020
Dec 23, 2020
34395_dirs_2020-12-23_70a74d65-e596-42af-bab5-79ed1b1082f7.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VOLITIONRX LTD (VNRX)
CIK: 0000093314
Period of Report: 2020-12-22
Reporting Person: Micallef Jacob Vincent (Chief Scientific Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-12-22 | Stock Option (Right to Buy) | $4 | G | 125000 | Disposed | 2022-04-15 | Common Stock (125000) | Indirect |
| 2020-12-22 | Stock Option (Right to Buy) | $4 | G | 125000 | Acquired | 2022-04-15 | Common Stock (125000) | Direct |
Footnotes
F1: The option to purchase an aggregate of 125,000 shares of Common Stock of VolitionRx Limited (the "Issuer"), was granted to Dr. Micallef on April 15, 2016 under the Issuer's 2015 Stock Incentive Plan and transferred to Borlaug Limited ("Borlaug"), a consulting firm, on April 20, 2016. Dr. Micallef is a controlling director of Borlaug and has voting and dispositive control over the Common Stock issuable to Borlaug upon the exercise of the option. The option was then transferred by Borlaug to Dr. Micallef on December 22, 2020.